

Exhibit 20

PRESS RELEASES

AMA, APhA, ASHP statement on ending use of ivermectin to treat COVID-19

SEP 1, 2021

WASHINGTON, DC – The American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) **strongly oppose the ordering, prescribing, or dispensing of ivermectin to prevent or treat COVID-19 outside of a clinical trial.**

Ivermectin is approved by the U.S. Food and Drug Administration (FDA) for human use to treat infections caused by internal and external parasites. It is not approved to prevent or treat COVID-19. Ivermectin is also available to treat certain veterinary conditions; medications formulated or intended for use in animals should not be used by humans. We are alarmed by reports that outpatient prescribing for and dispensing of ivermectin have increased 24-fold since before the pandemic and increased exponentially over the past few months. As such, we are calling for an immediate end to the prescribing, dispensing, and use of ivermectin for the prevention and treatment of COVID-19 outside of a clinical trial. In addition, we are urging physicians, pharmacists, and other prescribers—trusted health care professionals in their communities—to warn patients against the use of ivermectin outside of FDA-approved indications and guidance, whether intended for use in humans or animals, as well as purchasing ivermectin from online stores. Veterinary forms of this medication are highly concentrated for large animals and pose a significant toxicity risk for humans.

The U.S. [Centers for Disease Control and Prevention](#) (CDC) and the [FDA](#) have issued advisories indicating that ivermectin is not authorized or approved for the prevention

or treatment of COVID-19. The National Institutes of Health, World Health Organization, and Merck (the manufacturer of the drug) all state there is insufficient evidence to support the use of ivermectin to treat COVID-19. The Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 also recommend against the use of ivermectin outside of a clinical trial.

Use of ivermectin for the prevention and treatment of COVID-19 has been demonstrated to be harmful to patients. Calls to poison control centers due to ivermectin ingestion have increased five-fold from their pre-pandemic baseline. A recent CDC Health Alert Network Advisory (PDF) recommends that health care professionals should counsel patients against use of ivermectin as a treatment for COVID-19, including emphasizing the potentially toxic effects of this drug, including “nausea, vomiting, and diarrhea. Overdoses are associated with hypotension and neurologic effects such as decreased consciousness, confusion, hallucinations, seizures, coma, and death.”

For more information, we encourage patients and health care providers to consult the FDA’s Consumer Update on Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 and the CDC Health Alert Network Advisory on the Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Products Containing Ivermectin to Prevent or Treat COVID-19.

Patients are encouraged to talk to their physicians, pharmacists, and other prescribers about currently available therapies authorized or approved for the treatment or prevention of COVID-19. The most effective ways to limit the spread of COVID-19 are to get vaccinated, wear a face mask, stay at least six feet from others in public places, wash hands frequently, and avoid large crowds of people. Our organizations strongly urge eligible unvaccinated individuals to get vaccinated.

[AMA COVID-19 Resource Center for Physicians](#)

[APhA COVID-19 Resource Center](#)

[ASHP COVID-19 Resource Center](#)

Media Contact:

AMA Media & Editorial
ph: (312) 464-4430

media@ama-assn.org

About the American Medical Association

The American Medical Association is the physicians' powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.

More about:

[COVID-19 Medication & Treatment Guidance](#)

[Coronavirus \(COVID-19\)](#)

[Coronavirus Masking in Public](#)


[Coronavirus Vaccines](#)

FEATURED STORIES



PUBLIC HEALTH

3 tips for doctors on using Evusheld for COVID-19 protection



USMLE

4 essential tips for your final weeks of Step 1 study



PATIENT SUPPORT ADVOCACY

Membership Moves Medicine™

On advance directives, doctors should be role models for patients

Free access to JAMA Network™ and CME

Save hundreds on insurance

Fight for physicians and patient rights

Join the AMA today

Also of Interest:

What doctors wish patients knew about...

The AMA promotes the art and science of medicine and the betterment of public health.

AMA Contact Us

Download AMA Connect app for **iPhone** or **Android**

AMA Careers

Events

Press Center

AMA Alliance

AMPAC

AMA Foundation

The best in medicine, delivered to your mailbox

Email Address

Subscribe

☐

I verify that I'm in the U.S. and agree to receive communication from the AMA or third parties on behalf of AMA.

JAMA NETWORK™ | FREIDA™ | AMA ED HUB™ | COVID-19 RESOURCES |
COVID-19 CPT® CODES | AMA JOURNAL OF ETHICS® | CPT | STORE |
AMA PHYSICIAN PROFILES

Terms of Use | Privacy Policy | Code of Conduct | Website Accessibility

Copyright 1995 - 2022 American Medical Association. All rights reserved.